Psychiatry's Medication Pipeline in Motion.
The article provides updates on medications used for psychiatric conditions. These include N-methyl-D-aspartate (NMDA)-glutamate antagonism/Sigma-1 agonism for agitation in dementia, as well as norepinephrine, dopamine and serotonin reuptake inhibitors for the treatment of attention-deficit/hyperact...
| Publicado en: | Psychiatric Times Vol. 43; no. 5; pp. 6 - 10 |
|---|---|
| Autor principal: | |
| Formato: | Artículo |
| Publicado: |
MJH Life Sciences
May2026
|
| Materias: | |
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ssf&AN=193487506&site=ehost-live header: @attributes: shortDbName: ssf uiTerm: 193487506 longDbName: Social Sciences Full Text (H.W. Wilson) uiTag: AN controlInfo: bkinfo: jinfo: jid: 08932905 8MJ jtl: Psychiatric Times issn: 08932905 maglogo: N pubinfo: dt: May2026 vid: 43 iid: 5 pid: 54670 pub: MJH Life Sciences artinfo: ui: 193487506 ppf: 6 ppct: 4 formats: fmt: @attributes: type: P size: 2.8MB tig: atl: Psychiatry's Medication Pipeline in Motion. aug: au: Miller, John J. su: United States. Food & Drug Administration Mental illness drug therapy Attention-deficit hyperactivity disorder Agitation (Psychology) Hallucinogenic drugs Medical research Mental depression Drug therapy for schizophrenia Investigational drugs Antipsychotic agents Drug approval Drug development Dementia Cholinergic receptors Disease complications sug: subj: Mental illness drug therapy Attention-deficit hyperactivity disorder Agitation (Psychology) Hallucinogenic drugs Medical research Mental depression United States. Food & Drug Administration Pharmaceutical and medicine manufacturing Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology) Research and development in the physical, engineering and life sciences Drug therapy for schizophrenia Investigational drugs Antipsychotic agents Drug approval Drug development Dementia Cholinergic receptors Disease complications ab: The article provides updates on medications used for psychiatric conditions. These include N-methyl-D-aspartate (NMDA)-glutamate antagonism/Sigma-1 agonism for agitation in dementia, as well as norepinephrine, dopamine and serotonin reuptake inhibitors for the treatment of attention-deficit/hyperactivity disorder (ADHD), and opioid K receptor antagonism and α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor potentiator for major depressive disorder. pubtype: Academic Journal doctype: Article src: R language: English refInfo: copyright: @attributes: flag: N holdings: @attributes: islocal: N |
|---|